The human T cell leukemia-lymphoma virus (HTLV) l is a novel retrovirus associated with adult T cell leukemia (ATL) and lymphoma and shows a unique geographical distribution to southern Japan, the southeastern United States, the West Indies, and other areas (1) . Studies using HTLV-associated patient serum (2-4) or a monoclonal antibody (12/1-2) against a 19,000 dalton component of HTLV (p19) (5, 6) , as well as nucleic acid hybridization studies (7) (8) (9) , have demonstrated that HTLV isolates from Japanese ATL and cutaneous T cell lymphoma from patients in the U. S. are highly related or identical. Serological studies demonstrated HTLV-associated patient sera immunoprecipitated HTLV proteins of 19,000 and 24,000 daltons from 125I-labeled HTLV preparations (10) , and that both p19 and p24 copurify with viral core structures, suggesting that they are structural core proteins of HTLV (11) . Data from the complete nucleotide sequence of the proviral HTLV genome (12) as well as partial amino acid analysis of the p24 protein of HTLV (13, 14) indicate further that HTLV proteins p19 and p24 are encoded by the gag region of the viral genome.
Monoclonal antibody 12/1-2, which reacts with the p19 core protein of HTLV, has been a useful diagnostic reagent for the detection of HTLV-infected T cells (5, 6) . However, the antigenic determinant recognized by monoclonal antibody 12/1-2 is also present on normal thymic epithelium and on other normal and neoplastic epithelial cells, and therefore is not strictly HTLV specific (15) . In addition, no anti-HTLV p24 monoclonal antibodies have been made, and only limited quantities of polyclonal goat antiserum to HTLV p24 core protein are available as a probe for the detection of p24 in HTLV-infected cells. Moreover, use of the polyclonal goat anti-p24 in fluorescent assays has not been useful for HTLV cellular localization (10) . Thus, in the present study, we raised monoclonal antibodies against HTLV p24 and used them as diagnostic reagents for detection of HTLV-infected cells, to study the cellular localization of p24, and to evaluate whether there is any shared antigenicity between p24 and normal human tissue, as has been found for HTLV p19 (15) . We report here that four monoclonal antibodies (HTLV 6, 7, 8, and 9) raised against disrupted HTLV reacted with the p24 internal core protein of HTLV and with HTLV-infected T cells, but did not react with a wide range of normal, neoplastic, or non-HTLV-infected human cells and tissues. In addition, monoclonal antibodies HTLV 6, 7, 8, and 9 identified at least two antigenic sites on HTLV p24 that are both recognized by antibodies in HTLV + patient sera. Antibodies HTLV 6, 7, 8, and 9 also reacted with a T cell line from umbilical cord blood infected with HTLV-IIMo, a new type of HTLV. This virus was located from a patient (MO) with a T cell variant of hairy cell leukemia. Finally, HTLV p24 internal core protein was localized at the cell surface of HTLV-infected T cells and is likely associated with areas of budding virus particles.
Materials and Methods
Production of Monoclonal Antibodies. On days 0, 7, 14, and 21, BALB/c mice were immunized with subcutaneous and footpad injections of 50 t~g disrupted HTLV (see below) in complete (day 0) and incomplete (days 7, 14, and 21) Freund's adjuvant. Before fusion, sera from immunized mice were screened for antibodies to HTLV by solid-phase radioimmunoassay (RIA) (6) and radioimmunoprecipitation (RIP) assay (16) . Spleen cells from mice with circulating antibodies to HTLV were fused with one of the myeloma cell lines P3/63/Ag8, NS1-Ag4, or 653, using polyethylene glycol 1000 as previously described (17) . After 10-14 d, colony supernatants were screened for anti-HTLV antibodies by solid-phase RIA. Positive colonies were passaged into 24-well plates and rescreened for reactivity to disrupted HTLV using the RIP assay or the Western blotting technique described below. Positive colonies were cloned by limiting dilution until successive cionings gave 100% positive cultures, and then passaged as ascites tumors.
Tissue and Cell Suspension Assays for Anti-HTLV Antibody Reactivity. Hybridoma supernatants and ascitic fluid were screened for reactivity with 4-um frozen sections from a wide variety of types of tissues using indirect immunofluorescence as previously described (18) . In some experiments, antibody HTLV 6 was directly fluoresceinated (fluorescein/ protein ratio [F/P], 5.6) and used in direct fluorescence as described (18, 19) . HUT 102, HUT 78, EB-3, SB, and HSB-2 cell lines were obtained and cultured as described (19) . Cytocentrifuge preparations of cell lines, Hypaque-Ficoll-purified fresh normal peripheral blood leukocytes (PBL), and HTLV ÷ patient PBL cultured in 25% T cell growth factor (Enzyme Center, Boston, MA) for 5 d were prepared, acetone fixed, and assayed for reactivity with anti-HTLV monoclonal antibodies or P3/63 control ascites fluid as previously described (10) .
Viral Preparations and Antibody Reagents. HTLV was collected from HTLV + HUT 102 cell culture supernatants by continuous flow centrifugation and was purified by banding on sucrose density gradients as previously described (20) . The virus was disrupted in Triton X-100 as described (16) and used in RIP or Western blot assays or extracted once with a threefold volume of diethyl ether and used in the solid-phase RIA. Goat polyclonai antisera against purified p24 and monoclonai antibody 12/1-2 that reacts with HTLV p 19 core protein (5) were the generous gifts of Dr. V. Kalyanaraman and Dr. M. RobertGuroff (NCI, NIH), respectively. HTLV ÷ patient serum used in preclearing experiments was from patient SD with Japanese ATL (10) .
Solid-Phase R/A. A solid-phase RIA (6) was used to detect hybridoma cell supernatants containing antibodies to HTLV proteins. An ether-extracted HTLV protein preparation was diluted in 15 mM NaHCO3, 35 mM Na~COs, pH 9.6 (coating buffer), and 100 ng in 50 #1 coating buffer was added to detachable wells of Immulon plastic microtiter well strips (Dynatech Laboratories, Inc., Alexandria, VA). After overnight absorption at 4°C, wells were washed and incubated for 2 h at 4°C in coating buffer with 3% bovine serum albumin (BSA) and 0.02% NaN3 to block nonspecific protein binding sites. Plates were stored at -20°C until used. Before assay, plate wells were washed three times with 100 #i of phosphate-buffered saline (PBS), pH 7.2, containing 0.5% Tween 20, 0.1% BSA, and 0.1% NaNs (PBS wash), and incubated for 1 h at 23 °C with 50 #1 ofhybridoma supernatant diluted 1:2 in PBS, 0.5% Tween 20, 1% BSA, 0.1% NaNs (PBS diluent). After washing, 1:200 to 1:500 dilutions of rabbit anti-mouse IgG + M whole serum (Cappei Laboratories, Cochranville, PA) in PBS diluent were added and incubated for 30 min at 23°C. Plate wells were washed and incubated with 100,000 cpm of l~I-protein A in 50 gi of PBS diluent for 30 min at 23°C. Wells were emptied, washed five times with PBS wash, separated, and counted for 1 min in a gamma counter.
Studies of Antigenic Sites on HTLV p24 Identified by HTLV 6, 7, 8, and 9 and by HTLV + Patient Sera. Monoclonal antibodies HTLV 6, 7, 8, and 9 were isolated from mouse ascites fluid using protein A-Sepharose (21) and were iodinated using Iodobeads (Pierce Chemical Co., Rockford, IL). A competitive inhibition assay to compare the reactivities of HTLV 6, 7, and 8 and HTLV ÷ patient sera to antigenic sites on HTLV p24 was performed as previously described (6) with some modifications. Briefly, duplicate microtiter wells precoated with HTLV proteins (1-2 #g/well) as described above were incubated with dilutions of unlabeled HTLV 6, 7, 8, and 9 or HTLV + patient sera in PBS diluent buffer for 45 min at 23°C. Wells were washed with PBS wash buffer and then further incubated with 105 cpm of 125I-labeled HTLV 6, 7, 8, or 9 in PBS diluent buffer for 45 rain at 23°C. Wells were washed as before and counted in a gamma counter. For controls, HTLV-coated wells were incubated with dilutions of P3X63 ascites fluid or pooled normal human serum and then used in the assay to estimate 100% binding of radiolabeled antibody. To estimate 0% binding of the radiolabeled antibody, HTLV-coated wells were incubated with a 1:100 dilution of the appropriate unlabeled anti-p24 antibody and the assay was completed as described.
Radioimmunoprecipitation of 125I-HTLV. HTLV preparations were iodinated with Iodogen (Pierce Chemical Co.) in the following manner: Briefly, 10 #g of Iodogen in 100 #l chloroform was dried to the bottom of a 12 x 75-mm test tube under a stream of dry nitrogen and tubes were stored at 4°C in a dessicator until used. For labeling, 10 #g of HTLV protein in 10 #1 PBS, pH 7.2, were incubated in Iodogen-coated tubes for 15 rain at 23°C with 0.5 mCi 125I (Amersham Corp., Arlington Heights, IL). The mixture was passed over a PD-10 column (Pharmacia Inc., Piscataway, NJ) equilibrated with RIP buffer (10 mM sodium phosphate, pH 7.5, 300 mM NaC1, 0.2% Triton X-100, 0.01% Tween 80, 0.1% gelatin, 0.02% NaNs) and labeled HTLV proteins were eluted with RIP buffer and stored at -20°C. For screening of sera from mice immunized with HTLV, 5 #l of test or normal control serum was added to 500 #l of RIP buffer containing 5 × 105 cpm of ~25I-HTLV and incubated overnight at 4°C. Immune complexes were precipitated by adding 100 #1 of 10% fixed Staphylococcus aureus Cowan I strain (SAC) (Pansorbin; Calbiochem-Behring Corp., La Jolla, CA) in RIP buffer and incubating for 1 h at 4°C. Pellets were washed three times in RIP buffer and immunoprecipitates were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (22) on 10% polyacrylamide gels.
Predearing of I~5I-HTLV with anti-HTLV Monoclonal Antibodies or HTLV + ATL Patient Serum.
To compare the reactivity of antibodies in sera of patients with HTLV with that of murine monocional antibodies raised to HTLV, preclearing experiments were undertaken in the following manner. To compare antibody A with antibody B, 5 x 105 cpm of ~25I-HTLV in 500 #! of RIP buffer were incubated overnight with the amount of antibody A that resulted in optimum precipitation of ~5I-HTLV, as determined by titration studies. To determine optimum preclearing conditions for precipitation of ~25I-HTLV with monoclonal antibodies or patient serum, titration curves were derived using 0.5-40 #1 of monoclonal antibody ascites or patient serum, 5 × 105 cpm of 125I-HTLV in 500 #! of RIP buffer, and 100 ~i of 10% SAC. All antibody precipitations were done overnight at 4°C. To immunoprecipitate HTLV p24 optimally with HTLV 7, 8, or 9, immunoprecipitation was performed with SAC precoated with rabbit anti-mouse IgG + IgM (23) . The amount of antibody that precipitated the maximum number of counts in titration studies was used in preclearing experiments described below. After precipitation of immune complexes with SAC, the precleared 12~I-HTLV samples were again precipitated overnight with a half volume of antibody A and SAC, followed by an additional 1 h incubation with SAC alone. When preclearing with HTLV ÷ ATL patient serum, a third preclearing with a half volume of antibody plus SAC was required to preclear HTLV samples. For the final RIP, an optimum amount of antibody B plus SAC was added to the precleared ~25I-HTLV sample. For each preclearing experiment using antibodies A and B, the following controls were included: (a) preclearing with A and RIP with A, (b) preclearing with A and RIP with normal antibody control (normal human serum, normal mouse serum, or P3X63/Ag8 ascites) for A, (c) preclearing with A and RIP with B, (d) preclearing with A and RIP with normal antibody control for B (normal human serum, normal mouse serum, or P3X63/Ag8 ascites), (e) preclearing with normal control for A and RIP with A, (jr) preclearing with normal control for A and RIP with normal antibody control for A, (g) preclearing with normal antibody control for B and RIP with B, (h) preclearing with normal antibody control for B and RIP with normal antibody control for B, and (i) RIP with A and B and normal antibody controls without preclearing. Immunoprecipitates were electrophoresed on 10% polyacrylamide gels and autoradiographed for 2 d at -70°C using Kodak X-omat film and Dupont Lightning Plus intensifying screens.
Western Blotting of HTLV. Western blotting of HTLV was performed according to the technique of Towbin et al. (24) . Following SDS-PAGE of 0.5-2.5 t~g of disrupted HTLV protein under reducing or nonreducing conditions, HTLV proteins were electrophoretically transferred to nitrocellulose sheets (Schleicher & Schuell, Inc., Keene, NH) using an electrode buffer of 25 mM Tris, 192 mM glycine, 20% (vol/vol) methanol, pH 8.3, for 45 min at 0.7-0.9 A. Following the transfer, the nitrocellulose sheet was treated with 3% BSA in Tris-buffered saline (TBS) (0.9% NaC1, 10 mM Tris, pH 7.4) for 2 h at 23°C to block additional nonspecific protein binding sites. Individual lanes were then incubated with monoclonal antibody supernatants diluted 1:5 for 2 h at 23°C. Strips were then washed in TBS five times for 5 min each in 16 × 150 test tubes, incubated for 30 min at 23°C in 2 ml of 3% BSA-TBS containing 10 ~ cpm/ml of 125I-labeled sheep anti-mouse IgG + M F(ab')2 fragment (Amersham Corp.), washed five to eight times in TBS, blotted dry, and autoradiographed for 2 h with an intensifying screen. ~4C-labeled molecular weight markers that were transferred from the gel to the nitrocellulose served as internal molecular weight standards.
Electron Microscopy. HUT 102 cells were fixed by the addition of a volume of 2% glutaraldehyde in 0.1 M phosphate buffer with 1.8% sucrose equal to the volume of media in the flask. After 30 rain, cells were pelleted at low speed, and fresh 1% glutaraldehyde in phosphate/sucrose buffer was added for an additional 60 min. Postfixation was in 1% osmium tetroxide in phosphate buffer for 30 min followed by staining with 1% uranyl acetate in 0.11 M veronal acetate buffer for 30 min. Cells were embedded in EmBed 812 (Electron Microscopy Sciences, Ft. Washington, PA). Ultrathin sections were poststained with uranyl acetate and lead citrate and viewed in a Philips EM 300 electron microscope.
Results
Production of Anti-HTLV p24 Monoclonal Antibodies. After the fusion of mouse spleen cells with P3X63/Ag8, NS1-Ag4, or 653 rnyeloma cell lines, cells were plated into five 96-well microtiter plates per myeloma cell line. A total of 542 colony supernatants were screened in the solid-phase RIA for reactivity to HTLV proteins, 107 of which were positive. Four of the colony supernatants immuno-precipitated a 24,000 dalton protein (p24) from ~25I-labeled disrupted H T L V , and these colonies were cloned, passaged as mouse ascites tumors, and designated as antibodies H T L V 6, 7, 8, and 9. Table I shows the fusion parents and isotypes of the a n t i -H T L V p24 monoclonal antibodies produced.
Monoclonal antibodies H T L V 6, 7, 8, and 9 all reacted with a 24,000 dalton (p24) protein of H T L V when tested in the Western blotting procedure against reduced and blotted H T L V proteins (Fig. 1 ). H T L V 6, 7, 8, and 9 also reacted with a 24,000 dalton protein of H T L V under nonreducing conditions (data not shown). A control lane that contained blotted H T L V proteins was negative when similarly incubated with P3X63 ascites (Fig. 1D) .
T o further characterize monoclonal antibodies H T L V 6, 7, 8, and 9, the following criteria were established for reactivity with H T L V gag-encoded p24 internal core proteins: (a) Monoclonal anti-p24 antibodies should immunoprecipitate the same p24 H T L V protein that both H T L V + A T L patient (SD) serum and known polyclonal goat a n t i -H T L V p24 precipitate; and (b) monoclonal antip24 antibodies should react with H T L V -i n f e c t e d but not noninfected T cells grown in culture. Thus, preclearing studies were undertaken to compare the reactivities of H T L V 6, 7, 8, and 9 with those of H T L V + A T L patient (SD) serum and goat antiserum raised against H T L V p24. T o preclear H T L V p24 FIGURE l. Reactivity of monoclonal antibodies HTLV 6, 7, 8, and 9 with p24 of HTLV. SDS-PAGE of disrupted HTLV under reducing conditions and electrophoretic transfer to nitrocellulose were performed as described in Materials and Methods. After electrophoretic transfer of HTLV proteins, nitrocellulose strips were blocked with 3% BSA and incubated with hybridoma supernatants containing monoclonal antibody HTLV 6 (A), HTLV 7 (B), HTLV 9 (C), or supernatant from mouse myeloma cell line P3X63 as negative control (/9). Binding of monoclonal antibodies to blotted HTLV proteins was evaluated by incubating nitrocellulose strips with ~I-labeled F(ab')i fragment of sheep anti-mouse IgG + M, followed by washing and autoradiography for 2 h. HTLV 6, 7, and 9 recognized a 24,000 D protein of HTLV. HTLV 8 (not shown) also reacted with a p24 protein of HTLV in the Western blotting technique. '4C molecular weight markers were transferred to the nitrocellulose and used to derive molecular weight estimates. protein optimally from l~I-labeled disrupted HTLV with all polyclonal goat, patient, or murine monoclonal antibodies assayed, titration curves were first derived by precipitating radiolabeled H T L V proteins with varying amounts of antibody plus SAC. Fig. 2 shows a representative precipitation curve derived with monoclonal antibody HTLV-6. The amount of H T L V 6 ascites (10 ~1) that precipitated the maximum amount of l~SI-labeled p24 was used in subsequent preclearing studies. Similar titration curves were generated using SD serum, goat anti-p24, and H T L V 7, 8, and 9.
T o d e t e r m i n e whether SD serum and H T L V 6 precipitated the same 24,000 dalton protein, l~sI-iabeled H T L V samples (5 x 105 c p m / s a m p l e ) were extensively precleared by precipitation with SD serum and SAC. Precleared H T L V samples were then precipitated with H T L V 6 plus SAC, and immunoprecipitates were c o m p a r e d with those obtained with control antibodies on a 10% polyacrylamide gel (Fig. 3, left) . Preclearing Preclearing.. experiments, were, performed as described in Materials and Methods. Samples containing 5 x 10 ~ cpm of ~5I-labeled HTLV proteins were first precleared with HTLV 6 and then radioimmunoprecipitated with HTLV 7. Preclearing with HTLV 6 removed the p24 protein of HTLV recognized by HTLV 7 (C), while preclearing with P3X63 did not inhibit precipitation of p24 by HTLV 7 (F). Other controls are: (A) preclearing with HTLV 6, RIP with same; (B) preclearing with HTLV 6, RIP with P3X63; (D) preclearing with P3X63, RIP with HTLV 6; (E) preclear with P3X63, RIP with same. HTLV 6 also precleared the p24 protein precipitated by monoclonal antibodies HTLV-8 and HTLV 9 (data not shown). FIGURE ,5. Goat antiserum to purified HTLV p24 and HTLV 6 reacted with the same p24 protein of HTLV. Preclearing experiments were performed as described in Materials and 5 195 Methods. Samples containing 5 × 10 cpm of I-labeled HTLV proteins were precleared first with goat antiserum to purified p24 (goat anti-p24) and then precipitated (RIP) with HTLV 6. Preclearing with goat anti-p24 removed the p24 band recognized by HTLV 6 (C) while preclearing with normal goat serum (NGS) did not inhibit precipitation of p24 by HTLV 6 (G). noprecipitated with SD serum (Fig. 3, right) , the p24 band was selectively removed (lane C) from those proteins immunoprecipitated by SD serum (lane G), confirming that antibody HTLV 6 precipitated the HTLV p24 recognized by patient serum antibodies. Additional controls are shown in lanes A, B, D, F, and H (see figure legend) . The reactivity of HTLV 6 was then compared with reactivities of HTLV 7 in preclearing experiments shown in Fig. 4 . Preclearing of radiolabeled HTLV proteins with HTLV 6 removed the p24 protein recognized by HTLV 7 (Fig.  4 C) , while preclearing with control P3X63/Ag8 ascites did not remove the p24 protein recognized by HTLV 7 (Fig. 4F) . In similar experiments, HTLV 6 also precleared the p24 protein recognized by HTLV 8 and HTLV 9, indicating that monoclonal antibodies HTLV 6, 7, 8, and 9 all react with the same p24 protein.
To further demonstrate that HTLV 6 reacts with the p24 internal core protein of HTLV, preclearing experiments were undertaken using goat antiserum raised to purified HTLV p24. As shown in Fig. 5 , the goat antiserum to p24 precleared the p24 protein recognized by HTLV 6 (Fig. 5 C) , whereas preclearing with the normal goat serum did not affect the subsequent precipitation of p24 by HTLV 6 (Fig. 5 G) . In contrast, preclearing with monoclonal antibody 12/1-2 directed against the p19 protein of HTLV did not affect the sequential precipitation of p24 by HTLV 6, and preclearing with HTLV 6 did not inhibit precipitation of the p19 protein by monoclonal antibody 12/1-2 (data not shown).
To summarize the results of the preclearing experiments, monoclonal antibodies HTLV 6, 7, 8, and 9, goat anti-p24 antiserum and HTLV + ATL patient serum all reacted with the same p24 protein of HTLV.
Antigenic Sites on HTLV p24 Recognized by HTLV 6, 7, 8, and 9 and by HTLV + Patient Sera. To determine whether or not HTLV 6, 7, 8, and 9 recognize the same antigenic site or proximal sites on the p24 molecule, HTLV 6, 7, 8, and 9 were purified over protein A-Sepharose 4B columns, radiolabeled, and allowed to compete with unlabeled HTLV 6, 7, 8, and 9 for binding to HTLV p24 in a competitive inhibition plate assay (Fig. 6A-D) . As controls, competition experiments performed with dilutions of unlabeled P3X63 ascites fluid and ~25I-labeled HTLV 6, 7, 8, and 9 were used to estimate 100% binding in the plate assay. First, monoclonai antibodies HTLV 6 and 7, and to a lesser extent HTLV 8, inhibited the binding of z~SI-labeled HTLV 6 to HTLV p24 in a dose-dependent manner, while HTLV 9 did not inhibit binding (Fig. 6A) . We concluded that HTLV 6, 7, and possibly HTLV 8 recognized either the same or closely proximal antigenic sites on HTLV p24. Next, in the same assay, unlabeled HTLV 6, 7, and 8 each inhibited the binding of 125I-HTLV 7 (Fig. 6B ) and 125I-HTLV 8 (Fig. 6C) to HTLV p24, thus confirming that HTLV 6, 7, and 8 recognize either the same or closely proximal antigenic sites on p24. Neither HTLV 6 nor 7 inhibited the binding of ~2~I-HTLV 9 to p24, although HTLV 8 partially inhibited 12~I-HTLV 9 binding (Fig. 6D) . However, since unlabeled HTLV 9 did not inhibit the binding of ~25I-HTLV 6, 7, or 8 to HTLV p24 (Fig. 6A-C) , we concluded that HTLV 9 recognizes a different site than the site or sites recognized by HTLV 6, 7, and 8. Thus, at least two antigenic sites on HTLV p24 were identified by HTLV 6, 7, 8, and 9: site A, which appears to react only to HTLV p24 is inhibited by unlabeled HTLV 9 and by HTLV 8 at low dilutions, but not by HTLV 6 or 7. Since unlabeled HTLV 9 does not block the binding of ~251-HTLV 6, 7, or 8 to HTLV p24, it appears that HTLV 9 recognizes an antigenic site different from the site or sites recognized by HTLV 6, 7, and 8. Also, HTLV 6, 7, and 8 each inhibit the binding of x25I-HTLV 6, 7, and 8 to p24 and thus appear to recognize either the same antigenic site or proximal antigenic sites on the p24 molecule.
with antibody HTLV 9, and an additional antigenic site (site[s] B) identified by antibodies HTLV 6, 7, and 8.
To determine whether or not HTLV ÷ patient sera or other human sera positive for anti-HTLV antibodies recognize the same sites on HTLV p24 identified by monoclonal antibodies HTLV 6, 7, 8, and 9, human sera were used to inhibit the binding of 125I-HTLV 6, 7, 8, and 9 to HTLV p24 in a competitive binding assay. As shown in Table II , HTLV ÷ ATL or HTLV ÷ cutaneous T cell lymphoma patient serum partially inhibited the binding of ~25I-labeled HTLV 6, 7, 8, and 9 to HTLV p24. In addition, two sera obtained from clinically normal HTLV-infected family members of HTLV ÷ patients contained antibodies to HTLV p24 that also inhibited the binding of ]~I-HTLV 6, 7, 8, and 9 to p24. Other tissues tested in indirect immunofluorescence assays with HTLV 6, 7, 8, and 9 and found to be negative: thymus, lymph node, tonsil, spleen, kidney, liver, pancreas, adrenal, brain cortex and medulla oblongata, adenocarcinoma of lung and prostate, melanoma, breast carcinoma (3), and infiltrating T cells in skin from HTLV ÷ ATL patient SD. ! C3-44/MO is a T cell cord blood line infected with HTLVIIMo, a new type of HTLV (25) .
In contrast, pooled normal human serum did not inhibit binding of ~25I-HTLV 6, 7, 8, and 9 to p24. Thus, anti-p24 antibodies in HTLV + human sera reacted with antigenic sites on p24 that are also recognized by HTLV 6, 7, 8, and 9.
Tissue and Cellular Specificity of Anti-HTLV p24 Monoclonal Antibodies. Table III demonstrates that all four anti-p24 monoclonal reagents reacted only with the HTLV + malignant T cells tested and did not react with HTLV-T cells, fresh normal PBL, B cell lines, mitogen-activated normal T cells, or any of a large panel of normal human tissues. Also, HTLV 6, 7, 8 , and 9 reacted with acetone-fixed cord blood T cells (C3-44/Mo) that were infected with HTLVn, a new type of HTLV (25) . Thus, the antigenic sites of HTLV p24 identified by these antibodies are conserved in a cell line infected by HTLVn.
When treated with HTLV 6, 7, 8, and 9 in an indirect immunofluorescence assay, acetone-fixed HUT-102 HTLV-infected T cells demonstrated positive fluorescence localized in discrete patches at or near the cell surface or at the interface of cell to cell contact (arrows, Fig. 7 ). Also, 5% of H U T 102 cells appeared to contain intracytoplasmic fluorescence (arrowhead, Fig. 7 ). Type C virus particles were frequently seen between adjacent H U T 102 cells by electron microscopy (I 0) (arrows, Fig. 8 ) and probably account for the intense anti-p24 fluorescent staining localized between adjacent HUT-102 cells (Fig. 7) . In contrast, none of the anti-p24 monoclonal antibodies reacted with cell surface antigens on viable non-acetone-fixed HUT-102 cells in suspension, as shown by the fluorescence-activated cell sorter histogram in Fig. 9 . These data are compatible with the notion that p24 is an internal viral core protein and suggest that p24 is sequestered in budding virus particles at or near the surface of most HUT-102 cells.
Discussion
In this study we report the production and diagnostic use of four monoclonal antibodies to disrupted HTLV, HTLV 6, 7, 8, and 9, all of which reacted with the p24 internal core protein of HTLV. All four monoclonal antibodies reacted with the same p24 HTLV protein. Moreover, these antibodies all reacted with the same p24 HTLV protein recognized by antibodies in HTLV + ATL patient (SD) serum and by polyclonal goat antisera to purified HTLV p24 internal core FIGURE 7 . Immune fluorescence of HTLV ÷ acetone-fixed HUT-102 cells using monoclonal antibody HTLV 6. HTLV p24 was localized in discrete polar patches at or near the cell surface and between adjacent cells (arrows). Also, 5% of cells had intracytoplasmic anti-p24 fluorescence (arrowheads). Similar fluorescent staining of H U T 102 cells was also seen with HTLV 7, 8, and 9 (not shown). X 400. Fluorescence-activated cell sorter histogram of nonreactivity of monoclonal antibody HTLV 6 on viable HTLV ÷ HUT 102 cells, showing negative cell surface fluorescence. HUT 102 T cells were positive when stained for the presence of nonpolymorphic HLA with monoclonal antibody 3F 10. P 3 X 6 3 ascites fluid (---) was used as a negative control.
protein. Screening of H T L V 6, 7, 8, and 9 against a comprehensive panel of normal, neoplastic, and virus-infected human tissues and cells indicated that these monoclonal antibodies selectively identify only those cells that are infected with H T L V and express mature virions. A previous study (15) with monoclonal antibody 1 2 / 1 -2 directed against the p l 9 protein of H T L V demonstrated that antibody 1 2 / 1 -2 react with an antigenic determinant on normal n o n -H T L Vinfected human endocrine thymic epithelium and on the basal layer of keratinocytes in squamous epithelium (15) . In contrast, the reactivity o f monoclonal anti-HPLV p24 antibodies HTLV 6, 7, 8, and 9 is restricted to T cells infected with HTLV.
In competitive inhibition studies, HTLV 6, 7, and 8 recognized either the same antigenic site or proximal antigenic sites on HTLV p24, while HTLV 9 reacted with a unique site distinct from the site or sites recognized by HTLV 6, 7, and 8. Also, HTLV 6, 7, 8, and 9 reacted with fixed cord blood T (C3-44/ Mo) cells that were infected with HTLVm a human type C retrovirus reported to be a new type of HTLV (25) . Thus, the HTLV p24 antigenic sites identified by these antibodies are conserved in a cell line infected by HTLVII and are likely to be associated with the p24 of HTLVH. In addition, the antigenic determinants of p24 detected by our monoclonal antibodies are immunogenic in man, since HTLV ÷ patient sera blocked the binding of ~25I-labeled HTLV 6, 7, 8, and 9 to HTLV p24 in a competitive RIA.
Using anti-HTLV p24 antibodies, we have shown that HTLV p24 is localized at or near the cell surface of 95% of acetone-fixed HTLV ÷ HUT 102 cells. The p24 antigen was not detectable on the cell surface of viable HTLV ÷ cells, as demonstrated by data obtained with indirect fluorescence techniques and cell sorter analysis (Fig. 9) . Polar areas of HTLV ÷ T cells and areas between adjacent HUT 102 cells were strongly p24 positive by indirect immunofluorescence (Fig.  7) ; these are areas where HTLV virions frequently are demonstrated with electron microscopy (10) (Fig. 8) . These data suggest that HTLV p24 is sequestered in the virus particles budding from the surface of the HTLV-infected cells. In addition, monoclonal antibodies HTLV 6, 7, 8, and 9 and 12/1-2 (anti-HTLV p19) infrequently (5) react with diffuse cytoplasmic components of HTLV ÷ T cells. This may indicate that the precursor molecule encoded by the gag region of HTLV undergoes posttranslational modification at or near the cell membrane, thereby giving rise to the pl 9 and p24 epitopes defined by these monoclonal antibodies (26) . Finally, the use of directly fluoresceinated anti-HTLV p24 monoclonal antibodies in a one-step fluorescent assay on 5-d cultured PBL appears to be a simple and highly specific test for HTLV-infected cells.
It is hoped that these monoclonal antibodies will be useful diagnostic probes to detect HTLV-infected cells and to discriminate between the subtypes of HTLV associated with adult T cell leukemia, the T cell variant of hairy cell leukemia, and other diseases potentially associated with HTLV or variants of HTLV, such as the acquired immunodeficiency syndrome.
Summary
Four monoclonal antibodies, human T cell leukemia-lymphoma virus (HTLV) 6, 7, 8, and 9, which react with the 24,000 dalton internal core protein of HTLV~, have been developed. These monoclonal antibodies reacted with only HTLV-infected cells and not with a broad spectrum of normal, neoplastic, mitogen-stimulated, or virus-infected cells and tissues. HTLV 6, 7, 8, and 9 identified at least two different antigenic determinants on HTLV p24 that were also recognized by antibodies present in HTLV ÷ patient sera. Monoclonal antibodies HTLV 6, 7, 8, and 9 reacted in indirect immunofluorescence assays with HTLV p24 localized at the cell surface of 5-d cultures of HTLV-infected T cells and, as well, reacted with T cells infected with HTLVm a new type of HTLV isolated from a patient (MO) with a T cell variant of hairy cell leukemia. Thus, HTLV 6, 7, 8, and 9 should prove to be useful diagnostic reagents in the identification of HTLV-and HTLVn-infected T cells.
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